Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
FEMY vs BDX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
FEMY vs BDX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $13M | $55.53B |
| Revenue (TTM) | $2M | $21.36B |
| Net Income (TTM) | $-19M | $1.14B |
| Gross Margin | 62.0% | 46.5% |
| Operating Margin | -7.7% | 10.6% |
| Forward P/E | — | 12.3x |
| Total Debt | $5M | $19.18B |
| Cash & Equiv. | $9M | $851M |
FEMY vs BDX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Femasys Inc. (FEMY) | 100 | 5.5 | -94.5% |
| Becton, Dickinson a… (BDX) | 100 | 104.6 | +4.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FEMY vs BDX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FEMY is the clearest fit if your priority is growth exposure.
- Rev growth 40.8%, EPS growth 44.0%, 3Y rev CAGR 23.9%
- 40.8% revenue growth vs BDX's 8.2%
BDX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 0.66, yield 2.7%
- 80.2% 10Y total return vs FEMY's -96.3%
- Lower volatility, beta 0.66, Low D/E 75.5%, current ratio 1.11x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 40.8% revenue growth vs BDX's 8.2% | |
| Quality / Margins | 5.3% margin vs FEMY's -8.1% | |
| Stability / Safety | Beta 0.66 vs FEMY's 1.10, lower leverage | |
| Dividends | 2.7% yield; 1-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +51.8% vs FEMY's -60.6% | |
| Efficiency (ROA) | 2.1% ROA vs FEMY's -116.3%, ROIC 4.3% vs -347.4% |
FEMY vs BDX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FEMY vs BDX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — FEMY and BDX each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BDX is the larger business by revenue, generating $21.4B annually — 9316.2x FEMY's $2M. BDX is the more profitable business, keeping 5.3% of every revenue dollar as net income compared to FEMY's -8.1%. On growth, FEMY holds the edge at +39.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $2M | $21.4B |
| EBITDAEarnings before interest/tax | -$17M | $4.2B |
| Net IncomeAfter-tax profit | -$19M | $1.1B |
| Free Cash FlowCash after capex | -$19M | $3.1B |
| Gross MarginGross profit ÷ Revenue | +62.0% | +46.5% |
| Operating MarginEBIT ÷ Revenue | -7.7% | +10.6% |
| Net MarginNet income ÷ Revenue | -8.1% | +5.3% |
| FCF MarginFCF ÷ Revenue | -8.4% | +14.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +39.9% | -10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +69.9% | -2.0% |
Valuation Metrics
BDX leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $13M | $55.5B |
| Enterprise ValueMkt cap + debt − cash | $9M | $73.9B |
| Trailing P/EPrice ÷ TTM EPS | -0.96x | 26.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 12.27x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.59x |
| EV / EBITDAEnterprise value multiple | — | 14.65x |
| Price / SalesMarket cap ÷ Revenue | 5.77x | 2.54x |
| Price / BookPrice ÷ Book value/share | 3.03x | 1.73x |
| Price / FCFMarket cap ÷ FCF | — | 20.80x |
Profitability & Efficiency
BDX leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
BDX delivers a 4.5% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-5 for FEMY. BDX carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to FEMY's 0.80x. On the Piotroski fundamental quality scale (0–9), BDX scores 7/9 vs FEMY's 2/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -5.3% | +4.5% |
| ROA (TTM)Return on assets | -116.3% | +2.1% |
| ROICReturn on invested capital | -3.5% | +4.3% |
| ROCEReturn on capital employed | -167.9% | +5.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 |
| Debt / EquityFinancial leverage | 0.80x | 0.76x |
| Net DebtTotal debt minus cash | -$5M | $18.3B |
| Cash & Equiv.Liquid assets | $9M | $851M |
| Total DebtShort + long-term debt | $5M | $19.2B |
| Interest CoverageEBIT ÷ Interest expense | -8.85x | 4.09x |
Total Returns (Dividends Reinvested)
BDX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BDX five years ago would be worth $11,693 today (with dividends reinvested), compared to $374 for FEMY. Over the past 12 months, BDX leads with a +51.8% total return vs FEMY's -60.6%. The 3-year compound annual growth rate (CAGR) favors BDX at 1.6% vs FEMY's -15.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -29.5% | +0.7% |
| 1-Year ReturnPast 12 months | -60.6% | +51.8% |
| 3-Year ReturnCumulative with dividends | -40.1% | +5.0% |
| 5-Year ReturnCumulative with dividends | -96.3% | +16.9% |
| 10-Year ReturnCumulative with dividends | -96.3% | +80.2% |
| CAGR (3Y)Annualised 3-year return | -15.7% | +1.6% |
Risk & Volatility
BDX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than FEMY's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BDX currently trades 74.6% from its 52-week high vs FEMY's 38.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 0.66x |
| 52-Week HighHighest price in past year | $1.16 | $205.52 |
| 52-Week LowLowest price in past year | $0.31 | $100.31 |
| % of 52W HighCurrent price vs 52-week peak | +38.7% | +74.6% |
| RSI (14)Momentum oscillator 0–100 | 57.3 | 32.2 |
| Avg Volume (50D)Average daily shares traded | 513K | 2.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
BDX is the only dividend payer here at 2.72% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $172.85 |
| # AnalystsCovering analysts | — | 33 |
| Dividend YieldAnnual dividend ÷ price | — | +2.7% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $4.17 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.8% |
BDX leads in 4 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 1 category is tied.
FEMY vs BDX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is FEMY or BDX a better buy right now?
For growth investors, Femasys Inc.
(FEMY) is the stronger pick with 40. 8% revenue growth year-over-year, versus 8. 2% for Becton, Dickinson and Company (BDX). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate Becton, Dickinson and Company (BDX) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FEMY or BDX?
Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +16.
9%, compared to -96. 3% for Femasys Inc. (FEMY). Over 10 years, the gap is even starker: BDX returned +80. 2% versus FEMY's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FEMY or BDX?
By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.
66β versus Femasys Inc. 's 1. 10β — meaning FEMY is approximately 68% more volatile than BDX relative to the S&P 500. On balance sheet safety, Becton, Dickinson and Company (BDX) carries a lower debt/equity ratio of 76% versus 80% for Femasys Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — FEMY or BDX?
By revenue growth (latest reported year), Femasys Inc.
(FEMY) is pulling ahead at 40. 8% versus 8. 2% for Becton, Dickinson and Company (BDX). On earnings-per-share growth, the picture is similar: Femasys Inc. grew EPS 44. 0% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, FEMY leads at 23. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — FEMY or BDX?
Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.
7% net margin versus -812. 3% for Femasys Inc. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus -767. 0% for FEMY. At the gross margin level — before operating expenses — FEMY leads at 62. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — FEMY or BDX?
In this comparison, BDX (2.
7% yield) pays a dividend. FEMY does not pay a meaningful dividend and should not be held primarily for income.
07Is FEMY or BDX better for a retirement portfolio?
For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, FEMY: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between FEMY and BDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FEMY is a small-cap high-growth stock; BDX is a mid-cap quality compounder stock. BDX pays a dividend while FEMY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.